The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Between 2026 And 2030?
The market size for human leukocyte antigen (HLA) typing in oncology immunotherapy has shown significant expansion over recent years. It is anticipated to increase from $1.22 billion in 2025 to $1.31 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.8%. This historical growth can be linked to the rising global incidence of cancer, ongoing advancements in PCR and sequencing technologies, the increasing adoption of precision oncology strategies, an increase in clinical research dedicated to immunotherapies, and the broader application of biomarker-driven treatment selection.
The human leukocyte antigen (HLA) typing for oncology immunotherapy market is anticipated to experience robust expansion over the coming years. This market is set to reach $1.79 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.0%. The projected growth is driven by an expanding pipeline of cell and gene therapies, increased investment in personalized immunotherapy research, a rising demand for companion diagnostics, the global expansion of oncology clinical trials, and enhanced regulatory support for precision medicine. Noteworthy trends during this period include the wider adoption of next-generation sequencing-based HLA typing, greater integration of HLA profiling into adoptive T-cell therapies, increased utilization of high-resolution HLA typing in clinical trials, the proliferation of personalized cancer vaccine development, and a heightened focus on predictive immune compatibility testing.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Factors Are Influencing The Growth Of The Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market?
The increasing use of personalized medicine is anticipated to drive the expansion of the human leukocyte antigen (HLA) typing for oncology immunotherapy market in the future. Personalized medicine involves customizing medical care and health-related choices based on a person’s unique genetic, molecular, and clinical characteristics to achieve more accurate and beneficial treatment. The rise of personalized medicine is attributed to advancements in genomics, which empower medical professionals to detect genetic differences affecting disease susceptibility and drug reactions, leading to more focused and potent therapies. Human leukocyte antigen typing facilitates personalized oncology immunotherapy through the identification of a patient’s distinct immune makeup, allowing for the customization of treatments that enhance tumor antigen recognition and the immune response. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit, reported that the FDA cleared 16 new personalized therapies for rare disease patients in 2023, an increase from 6 in 2022. These approvals for 2023 encompassed 7 cancer drugs and 3 for other ailments and conditions. Consequently, the expanding uptake of personalized medicine is fueling the growth of the human leukocyte antigen (HLA) typing for oncology immunotherapy market.
How Are Segments Identified Within The Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Segment Framework?
The human leukocyte antigen (HLA) typing for oncology immunotherapy market covered in this report is segmented –
1) By Technology: Polymerase Chain Reaction (PCR)-Based, Sequencing-Based, Sequence-Specific Oligonucleotide (SSO), Sequence-Specific Primer (SSP), Other Technologies
2) By Product Type: Reagents And Kits, Instruments, Software
3) By Application: Cancer Diagnosis, Personalized Medicine, Research, Clinical Trials, Other Applications
4) By End-User: Hospitals And Diagnostic Laboratories, Research Institutes, Academic Centers, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By Polymerase Chain Reaction Based: Real Time Polymerase Chain Reaction, Nested Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Digital Polymerase Chain Reaction
2) By Sequencing Based: Next Generation Sequencing, Sanger Sequencing, Whole Genome Sequencing, Targeted Gene Sequencing
3) By Sequence Specific Oligonucleotide: Luminex Based Sequence Specific Oligonucleotide, Microarray Based Sequence Specific Oligonucleotide, Bead Based Sequence Specific Oligonucleotide, Plate Based Sequence Specific Oligonucleotide
4) By Sequence Specific Primer: Conventional Sequence Specific Primer, Multiplex Sequence Specific Primer, Real Time Sequence Specific Primer, Nested Sequence Specific Primer
5) By Other Technologies: Flow Cytometry Based Typing, Mass Spectrometry Based Typing, Immunoassay Based Typing, Hybridization Based Typing
What Trends Are Transforming The Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market?
Companies operating in the human leukocyte antigen (HLA) typing for oncology immunotherapy market are concentrating on developing innovative solutions, such as allele-specific patient selection, to improve personalized immunotherapy efficacy and clinical outcomes. Allele-specific patient selection involves identifying patients based on their specific HLA gene variants to customize immunotherapy for optimal effectiveness. For instance, in August 2024, Thermo Fisher Scientific Inc., a US-based biotechnology company, received approval from the FDA for the SeCore HLA typing kit to be used as a companion diagnostic with a T-cell receptor therapy for synovial sarcoma. This approval broadens HLA sequencing’s application from transplant diagnostics into oncology immunotherapy by enabling precise patient selection for TCR-based treatments targeting tumor antigens.
Who Are The Companies Competing Within The Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market?
Major companies operating in the human leukocyte antigen (HLA) typing for oncology immunotherapy market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson Company, Eurofins Scientific SE, Illumina Inc., Werfen, QIAGEN N.V., Versiti Inc., CareDx Inc., Oxford Nanopore Technologies Plc., Pacific Biosciences of California Inc., Takara Bio Inc., HistoGenetics LLC, Biofortuna Limited, Bio-Rad Laboratories Inc., DKMS Life Science Lab, ClinImmune Inc., BGI Genomics Co. Ltd., Immudex A/S, ProImmune Ltd.
Get The Full Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Report:
Which Region Holds The Highest Market Share In The Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market?
North America was the largest region in the human leukocyte antigen (HLA) typing for oncology immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human leukocyte antigen (HLA) typing for oncology immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market 2026, By The Business Research Company
pruritus therapeutic market report 2026
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
genomic urine testing market report 2026
https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report
ocular genetic diagnostic market report 2026
https://www.thebusinessresearchcompany.com/report/ocular-genetic-diagnostic-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
